Download PDF
Klinische Neurophysiologie 2004; 35(4): 245-249
DOI: 10.1055/s-2004-834537
Originalia
© Georg Thieme Verlag KG Stuttgart · New York

Zentraler Deafferenzierungsschmerz: Klinisches Bild und Therapie

Symptoms and Treatment of Central PainA.  Frese1 , E.  B.  Ringelstein1
  • 1Klinik und Poliklinik für Neurologie, Universitätsklinikum Münster
Further Information

Publication History

Publication Date:
06 December 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Zentraler Deafferenzierungsschmerz kann grundsätzlich nach jeder Läsion im Verlauf der zentralen Schmerzbahn entstehen. Leitsymptom ist ein konstanter oder intermittierender Schmerz mit sensiblen Auffälligkeiten im schmerzhaften Körperteil. Eine Allodynie ist pathognomonisch für alle Arten des neuropathischen Schmerzes; sie ist in mehr als der Hälfte der Fälle von zentralem Deafferenzierungsschmerz vorhanden. Realistisches Therapieziel ist eine Linderung der Schmerzen, Schmerzfreiheit hingegen ist selten erreichbar. Es gibt nur wenige kontrollierte Studien an relativ kleinen Patientenkollektiven. Die Wirksamkeit von Amitriptylin und Lamotrigin in der Behandlung zentraler Deafferenzierungsschmerzen wurde in plazebokontrollierten Studien nachgewiesen. Diese Substanzen sind daher Mittel der ersten Wahl. Für Gabapentin zeigte eine offene Studie eine Wirksamkeit, ebenso für Mexiletin als Add-on-Therapie zusammen mit Antidepressiva. Häufig ist eine Kombinationstherapie notwendig. Sie sollte immer begleitet sein von Rehabilitationsmaßnahmen, insbesondere Bewegungstherapie, und der Beseitigung zusätzlicher nozizeptiver Schmerzquellen. Nach Ausschöpfen aller medikamentösen Behandlungsoptionen verbleiben invasive Therapiemaßnahmen als Ultima Ratio, z. B. Thalamusstimulation, Motokortexstimulation, Rückenmarkstimulation. Ihre Erfolge sind jedoch häufig zeitlich limitiert.

Abstract

Central pain can occur following lesions anywhere in the spinothalamic pathway and its corticopetal projections. It is characterized by constant or intermitted pain in association with sensory abnormalities in the painful part of the body. Allodynia is a classic hallmark that is present in more than 50 % of patients with central pain. Pain reduction rather than pain relief is the goal of the treatment. Randomized controlled trials are rare and include only small numbers of patients. Amitriptyline and lamotrigine have proven to be effective in placebo-controlled randomised trials and are the drugs of first choice. Gabapentin has demonstrated promising effects in an open study, as well as Mexiletine added-on to antidepressants. Combination therapy is often needed and should always be accompanied by a comprehensive rehabilitation program and an accurate search for and treatment of accompanying sources of nociceptive pain. If drug treatment fails, surgical interventions like deep brain stimulation, cortical stimulation, or spinal cord stimulation can be the ultima ratio. Unfortunately, with these later therapies, recurrence of pain after months or years is common.

Key words

Central pain - neuropathic pain - mechanisms - therapy

Literatur

  • 1 Dejerine J, Roussy J. Le syndrome thalamique.  Rev Neurol. 1906;  14 521-532
    PubMedGoogle Scholar
  • 2 Foix C, Chavany J-A, Lévy M. Syndrome pseudo-thalamique d'origine pariétale. Lésion de l'artère du sillon interpariétal. Paris: CR Soc Neurol 1927: 168-175
    Google Scholar
  • 3 Cassinari V, Pagni C A. Central pain. A neurosurgical survey. Cambridge (MA); Harvard University Press 1969
    Google Scholar
  • 4 Bowsher D, Leijon G, Thuomas K A. Central poststroke pain: correlation of MRI with clinical pain characteristics and sensory abnormalities.  Neurology. 1998;  51 1352-1358
    CrossrefPubMedGoogle Scholar
  • 5 Kumral E, Kocaer T, Ertübey N. et al . Thalamic hemorrhage: a prospective study of 100 patients.  Stroke. 1995;  26 964-970
    PubMedGoogle Scholar
  • 6 Nasreddine Z S, Saver J L. Pain after thalamic stroke: right diencephalic predominance and clinical features in 180 patients.  Neurology. 1997;  48 1196-1199
    PubMedGoogle Scholar
  • 7 Andersen G, Vestergaard K, Ingeman-Nielsen M. et al . Incidence of central post-stroke pain.  Pain. 1995;  61 187-193
    CrossrefPubMedGoogle Scholar
  • 8 Ringelstein E B. Zentraler Deafferenzierungsschmerz (Thalamusschmerz). In: Gralow I, Husstedt IW, Bothe HW, Evers S, Hürter A, Schilgen M (Hrsg) Schmerztherapie interdisziplinär. Stuttgart; Schattauer 2002: 208-219
    Google Scholar
  • 9 Bowsher D. Central pain: clinical and physiological characteristics.  J Neurol Neurosurg Psychiatry. 1996;  61 62-69
    PubMedGoogle Scholar
  • 10 Leijon G, Boivie J, Johansson I. Central post-stroke pain - neurological symptoms and pain characteristics.  Pain. 1989;  36 13-25
    CrossrefPubMedGoogle Scholar
  • 11 Gonzales G R. Suicide in central pain patients.  Neurology. 1994;  44, Suppl 2 A318
    PubMedGoogle Scholar
  • 12 Canavero S, Bonicalzi V, Massa-Micon B. Central neurogenic pruritus: a literature review.  Acta Neurol Belg. 1997;  97 244-257
    PubMedGoogle Scholar
  • 13 Eide P K, Jorum E, Stenehjem A E. Somatosensory findings in patients with spinal cord injury and central dysaesthesia pain.  J Neurol Neurosurg Psychiatry. 1996;  60 411-415
    PubMedGoogle Scholar
  • 14 Christensen M D, Hulsebosch C E. Chronic central apin after spinal cord injury.  Neurotrauma. 1997;  14 517-537
    PubMedGoogle Scholar
  • 15 Davis K D, Kiss Z H, Tasker R R. et al . Thalamic stimulation-evoked sensations in chronic pain patients and in non-pain (movement disorder) patients.  J Neurophysiol. 1996;  75 1026-1037
    PubMedGoogle Scholar
  • 16 Canavero S, Bonicalzi V. The neurochemistry of central pain: evidence from clinical studies, hypothesis and therapeutic implications.  Pain. 1998;  74 109-114
    CrossrefPubMedGoogle Scholar
  • 17 Budd K. The use of the opiate antagonist, haloxone, in the treatment of intractable pain.  Neuropeptides. 1985;  5 410-422
    PubMedGoogle Scholar
  • 18 Arner S, Meyerson B A. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain.  Pain. 1988;  33 11-23
    CrossrefPubMedGoogle Scholar
  • 19 Yamamoto T, Katayama Y, Hirayama T. et al . Pharmacological classification of central post-stroke pain: comparison with the results of chronic motor cortex stimulation.  Pain. 1997;  72 5-12
    CrossrefPubMedGoogle Scholar
  • 20 Attal N, Guirimand F, Brasseur L. et al . Effects of IV morphine in central pain.  Neurology. 2002;  58 554-563
    PubMedGoogle Scholar
  • 21 Rowbotham M, Twilling L, Davies P S. et al . Oral opioid therapy for chronic peripheral and central neuropathic pain.  New Engl J Med. 2003;  348 1223-1232
    CrossrefPubMedGoogle Scholar
  • 22 Leijon G, Boivie J. Central post-stroke pain - a controlled trial of amitriptyline and carbamazepine.  Pain. 1989;  36 27-36
    CrossrefPubMedGoogle Scholar
  • 23 Lampl C, Yazdi K, Röper C. Amitriptyline in the prophylaxis of central poststroke pain.  Stroke. 2003;  33 3030-3032
    PubMedGoogle Scholar
  • 24 Schott G D. From thalamic syndrome to central poststroke pain.  J Neurol Neurosurg Psychiatry. 1995;  61 560-564
    PubMedGoogle Scholar
  • 25 Bowsher D. The management of central post-stroke pain.  Postgrad Med J. 1995;  71 598-604
    PubMedGoogle Scholar
  • 26 Gonzales G R. Central pain: diagnosis and treatment strategies.  Neurology. 1995;  45, Suppl 9 S11-16
    PubMedGoogle Scholar
  • 27 Vestergaard K, Andersen G, Jensen T S. Treatment of central post-stroke pain with a selective serotonin reuptake inhibitor.  Eur J Neurol. 1996;  3, Suppl 5 169
    PubMedGoogle Scholar
  • 28 Shimodozono M, Kawahira K, Kamishita T. et al . Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine.  Intern J Neuroscience. 2002;  112 1173-1181
    PubMedGoogle Scholar
  • 29 Cantor F K. Phenytoin treatment of thalamic pain.  Br Med J. 1972;  840 590
    PubMedGoogle Scholar
  • 30 Mladinich E K. Diphenylhydantoin in the Wallenberg syndrome.  JAMA. 1974;  230 1230-1232
    PubMedGoogle Scholar
  • 31 Agnew D C, Goldberg V D. A brief trial of phenytoin therapy for thalamic pain.  Bull L A Neurol Soc. 1976;  41 9-12
    PubMedGoogle Scholar
  • 32 Vestergaard K, Andersen G, Gottrup H. et al . Lamotrigine for central poststroke pain. A randomized controlled trial.  Neurology. 2001;  56 184-190
    PubMedGoogle Scholar
  • 33 Canavero S, Bonicalzi V. Lamotrigine control of central pain.  Pain. 1996;  68 179-181
    CrossrefPubMedGoogle Scholar
  • 34 Carrieri P B, Provitera V, Lavorgna L. et al . Response of thalamic pain syndrome to lamotrigine.  Eur J Neurol. 1998;  5 625-626
    CrossrefPubMedGoogle Scholar
  • 35 Attal N, Parker F, Brasseur L. et al . Effects of gabapentin on the different components of neuropathic pain syndromes: a pilot study.  Europ Neurol. 1998;  40 191-200
    PubMedGoogle Scholar
  • 36 Holtom N. Gabapentin for treatment of thalamic pain syndrome.  Palliat Med. 2000;  14 167
    PubMedGoogle Scholar
  • 37 Herman R M, D'Luzansky S C, Ippolito R. Intrathecal baclofen suppresses central pain in patients with spinal lesions: a pilot study.  Clin J Pain. 1992;  8 338-345
    PubMedGoogle Scholar
  • 38 Taira T, Tanikawa T, Kawamura H. et al . Spinal intrathecal baclofen suppresses central pain after a stroke.  J Neurol Neurosurg Psychiatry. 1994;  57 381-382
    PubMedGoogle Scholar
  • 39 Taira T, Kawamura H, Tanikawa T. et al . A new approach to control central deafferentation pain: spinal intrathecal baclofen.  Stereotactic Funct Neurosurg. 1995;  65 101-105
    PubMedGoogle Scholar
  • 40 Awerbuch G I, Sandyk R. Mexiletine for thalamic pain syndrome.  Int J Neurosci. 1990;  55 129-133
    PubMedGoogle Scholar
  • 41 Chiou-Tan F Y, Tuel S M, Johnson J C. et al . Effect of mexiletine on spinal cord injury dysesthetic pain.  Am J Phys Med Rehabil. 1996;  75 84-87
    CrossrefPubMedGoogle Scholar
  • 42 Bowsher D, Nurmikko T. Central post-stroke pain. Drug treatment options.  CNS Drugs. 1996;  5 160-165
    PubMedGoogle Scholar
  • 43 Backonja M, Arndt G, Gombar K A. et al . Response of chronic neuropathic pain syndromes to ketamine: a preliminary study.  Pain. 1994;  56 51-57
    CrossrefPubMedGoogle Scholar
  • 44 Canavero S, Bonicalzi V, Pagni C A. et al . Propofol analgesia in central pain: preliminary clinical observations.  J Neurol. 1995;  242 561-567
    PubMedGoogle Scholar
  • 45 Attal N, Gaudé V, Brasseur L. et al . Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study.  Neurology. 2000;  54 564-574
    PubMedGoogle Scholar
  • 46 Kumar K, Toth C, Math R K. Deep brain stimulation for intractable pain: a 15-year experience.  Neurosurgery. 1997;  40 736-747
    PubMedGoogle Scholar
  • 47 Fujii M, Ohmoto Y, Kitahara T. et al . Motor cortex stimulation therapy in patients with thalamic pain.  No-Shinkei-Geka. 1997;  25 315-319 ,  (englischer Abstract)
    PubMedGoogle Scholar
  • 48 Katayama Y, Fukaya C, Yamamoto T. Post-stroke pain control by chronic motor cortex stimulation: neurological characteristics prediciting a favourable response.  J Neurosurg. 1998;  98 585-591
    PubMedGoogle Scholar
  • 49 Mertens P, Nuty C, Sindou M. et al . Precentral cortex stimulation for treatment of central neuropathic pain. Results of a prospective study in a 20-patients series.  Stereotact Funct Neurosurg. 1999;  73 122-125
    CrossrefPubMedGoogle Scholar
  • 50 Katayama Y, Yamamoto T, Kobayashi K. et al . Deep brain and motor cortex stimulation for post-stroke movement disorders and post-stroke pain.  Acta Neurochir Suppl. 2003;  87 121-123
    PubMedGoogle Scholar
  • 51 Migita K, Uozumi T, Arita K. et al . Transcranial magnetic stimulation of motor cortex in patients with central pain.  Neurosurgery. 1995;  36 1037-1040
    PubMedGoogle Scholar
  • 52 Taub E, Munz M, Tasker R R. Chronic electrical stimulation of the gasserian ganglion for the relief of pain in a series of 34 patients.  J Neurosurg. 1997;  86 197-202
    CrossrefPubMedGoogle Scholar
  • 53 Finnerup N B, Yezierski R P, Sang C N. et al .Treatment of spinal cord injury pain. Pain Clinical Updates, International Association for the Study of Pain. 2001, June 9 (2). Available at: http://www.iasp-pain.org/PCU01-2.html
    Google Scholar
  • 54 Peyron R, Garcia-Larrea L, Deiber M P. et al . Electrical stimulation of precentral cortical area in the treatment of central pain: electrophyiological and PET study.  Pain. 1995;  62 275-286
    CrossrefPubMedGoogle Scholar
  • 55 Ebert B, Andersen S, Krosgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl D-aspartate (NMDA) antagonists in the rat cortex and spinal cord.  Neurosci Lett. 2000;  295 21-24
    CrossrefPubMedGoogle Scholar
  • 56 Stringer M, Makin M K, Miles J. et al . D-Morphine, but not l-morphine, has low micromolecular affinity for the non-competitive N-methyl D-aspartate site in the rat forebrain. Possible clinical implications for the management of neuropathic pain.  Neurosci Lett. 2000;  295 21-24
    CrossrefPubMedGoogle Scholar

Dr. A. Frese

Klinik und Poliklinik für Neurologie · Universitätsklinikum Münster

Albert-Schweitzer-Straße 33

48129 Münster

Email: fresea@uni-muenster.de

      >